CELSR2 Gene Genetic Testing for Schizophrenia Risk Assessment in UAE | 2800 AED | 2026 DHA Guidelines

The CELSR2 gene encodes a cadherin receptor critical for neuronal migration and cortical patterning, and pathogenic variants in CELSR2 have been associated with disrupted neurodevelopment that significantly elevates lifetime schizophrenia risk.

Specifically, CELSR2 (Cadherin EGF LAG Seven-Pass G-Type Receptor 2) belongs to the flamingo subfamily of cadherins and governs planar cell polarity signalling during corticogenesis. Genome-wide association studies (GWAS) and whole-exome sequencing cohorts have identified rare loss-of-function and missense variants in CELSR2 that co-segregate with schizophrenia-spectrum phenotypes in multiplex families. This NGS test interrogates the entire gene to detect single nucleotide variants, small insertions/deletions, and copy-number alterations, providing clinicians with a molecular framework for risk stratification that is unattainable through clinical observation alone.

جين CELSR2 مسؤول عن تطور الخلايا العصبية وتنظيم الهجرة العصبية في القشرة الدماغية، والطفرات فيه ترتبط بزيادة خطر الإصابة بالفصام.

The test requires a simple blood draw, extracted DNA sample, or a single drop of blood on an FTA card, after which our laboratory performs full-gene Next-Generation Sequencing with orthogonal Sanger confirmation of all clinically reported variants.

Our VIP Mobile Phlebotomy team arrives at your home or office between 8:00 AM and 11:00 PM across all UAE Emirates. A trained phlebotomist collects 2–4 mL of whole blood in an EDTA tube using a single venipuncture. The sample is immediately placed in ISO-certified cold-chain transport (2–8°C) and delivered to our DHA-licensed facility within 4 hours. For patients who cannot provide blood, we accept pre-extracted DNA or a dried blood spot on an FTA card. Once received, DNA is extracted, quantified, and subjected to library preparation for sequencing on the Illumina NovaSeq X Plus platform at 100x minimum read depth. Bioinformatics analysis follows ACMG/AMP 2026 variant interpretation guidelines, and all Pathogenic and Likely Pathogenic variants are confirmed by Sanger sequencing before the final report is issued.

يتم إجراء الفحص من خلال سحب عينة دم بسيطة أو بقعة دم على بطاقة FTA، ثم تحليل الحمض النووي بتقنية التسلسل الجيني الشامل.

Results are delivered within 3 to 4 weeks and include a detailed clinical report classifying variants by ACMG pathogenicity tiers, accompanied by a complimentary telephonic consultation with a DHA-licensed neurologist for personalised interpretation.

Each report categorises detected variants into five tiers per ACMG/AMP 2026 standards: Pathogenic, Likely Pathogenic, Variant of Uncertain Significance (VUS), Likely Benign, and Benign. A Pathogenic finding in CELSR2 indicates a molecular confirmation of genetic susceptibility and should prompt comprehensive psychiatric evaluation and longitudinal monitoring. A VUS result means the laboratory identified a genetic change whose clinical significance is not yet fully understood — this is common in genomic medicine and does not rule out or confirm risk. A negative result (no Pathogenic or Likely Pathogenic variants detected) reduces but does not eliminate the possibility of schizophrenia, as other genes and environmental factors contribute to disease aetiology. All results include actionable clinical recommendations and, where indicated, guidance for cascade testing of at-risk relatives.

تصدر النتائج خلال 3 إلى 4 أسابيع مع تقرير سريري مفصل واستشارة هاتفية مجانية مع طبيب أعصاب مرخص من هيئة الصحة بدبي لتفسير النتائج.